Vera Therapeutics Inc. (VERA), a clinical-stage biotechnology company, has an upcoming clinical trial catalyst this quarter related to its lead investigational asset.
This company is developing transformative treatments for patients with serious immunological diseases. Its lead drug candidate is Atacicept, which is being developed for the treatment of certain autoimmune diseases, including IgAN.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com